A new research paper documents the outcomes of five volunteers who continued to receive 40Hz light and sound stimulation for around two years after participating in an MIT early-stage clinical study of the potential…
NEW ORLEANS — Treatment with the PCSK9 inhibitor alirocumab (Praluent) safely lowered LDL cholesterol versus placebo in…






